Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 3/20 | 0.38 |
| ▸ | S1PR4 known ✓ | O95977 | 1/20 | 0.38 |
| ▸ | BCHE known ✓ | P06276 | 1/20 | 0.38 |
| ▸ | S1PR1 known ✓ | P21453 | 1/20 | 0.38 |
| ▸ | PPARG known ✓ | P37231 | 1/20 | 0.38 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | S100A4 | P26447 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317892 | 0.97 | MAPT (0.40) | MAPTKMT2AMEN1LMNAMAOA | |
| Water SCHEMBL27460917 | 0.94 | MAPT (0.38) | MAPTKMT2AMEN1LMNAMAOA | |
| SCHEMBL21359837 | 0.94 | MAPT (0.38) | MAPTKMT2AMEN1LMNAMAOA | |
| Bicarbonate SCHEMBL9542773 | 0.86 | NPSR1 (0.39) | MAPTKMT2AMEN1LMNAPOLB | |
| Phosphonic Acid SCHEMBL2459322 | 0.84 | MAPT (0.35) | MAPTKMT2AMEN1LMNAMAOA | |
| Hydrochloric Acid SCHEMBL4647777 | 0.81 | APAF1 (0.33) | MAPTKMT2AMEN1LMNAMAOA | |
| SCHEMBL9093165 | 0.80 | LMNA (0.37) | MAPTKMT2AMEN1LMNAMAOA | |
| SCHEMBL28072669 | 0.78 | MEN1 (0.35) | MAPTKMT2AMEN1LMNAMAOA | |
| SCHEMBL37950 | 0.78 | MEN1 (0.35) | MAPTKMT2AMEN1LMNAMAOA | |
| Benzylamine SCHEMBL7955985 | 0.77 | LOXL2 (0.58) | MAOASMN1; SMN2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019177117-A1 | DRUG FOR TREATING COUGH | 日本ケミファ株式会社 | 2019-09-19 | — | — | WO | claimed |
| EP-0664807-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS. | WARNER LAMBERT CO (US) | 1995-08-02 | — | — | EP | claimed |
| WO-1994009000-A1 | QUINOXALINEDIONE DERIVATIVES AS EAA ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1994-04-28 | — | — | WO | claimed |
| WO-2019177117-A1 | DRUG FOR TREATING COUGH | 日本ケミファ株式会社 | 2019-09-19 | — | — | WO | disclosed |
| CN-109414503-A | The pharmaceuticals for the treatment of for multiple sclerosis | 日本化学药品株式会社 | 2019-03-01 | — | — | CN | disclosed |
| CN-103237794-B | P2X4Receptor antagonists | 日本化学医药株式会社 | 2016-07-06 | — | — | CN | disclosed |
| CN-103237794-A | P2X4Receptor antagonists | NIPPONCHEMIPHAR CO LTD | 2013-08-07 | — | — | CN | disclosed |
| US-7750024-B2 | Remedy for glioblastoma | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| CN-1298704-C | Isatine derivatives with neurotrophic activity | NEUROSEARCH AS (DK) | 2007-02-07 | — | — | CN | disclosed |
| US-20050165009-A1 | Remedy for glioblastoma | ASTELLAS PHARMA INC. (JP) | 2005-07-28 | — | — | US | disclosed |
| CN-1395563-A | Isatine derivatives with neurotrophic activity | NEUROSEARCH AS (DK) | 2003-02-05 | — | — | CN | disclosed |
| CN-1222154-A | Imidazole-substituted quinoxalinedione derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1999-07-07 | — | — | CN | disclosed |
| WO-1998005651-A1 | NOVEL GLUTAMATE RECEPTOR ANTAGONISTS: FUSED CYCLOALKYL QUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1998-02-12 | — | — | WO | disclosed |
| WO-1996017832-A1 | NOVEL GLUTAMATE RECEPTOR ANTAGONISTS: FUSED CYCLOALKYLQUINOXALINEDIONES | WARNER-LAMBERT COMPANY (US) | 1996-06-13 | — | — | WO | disclosed |
| EP-0642508-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165009-A1 | Remedy for glioblastoma | GRM2, GRM1, GRM3 | MAOA 3365/4885S1PR4 1190/4885BCHE 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.